JAN 15, 2020 11:57 AM PST

Acid-Reflux Drugs May Negatively Impact Breast Cancer Survivors

WRITTEN BY: Nouran Amin

Many of us have taken some form of an acid-reflux drug—especially after a meal that causes discomfort. However, now researchers are indicating that survivors of breast cancer who take proton pump inhibitors (PPIs)-based drugs for acid-reflux, which may sometimes ease stomach problems caused by cancer treatment, may face an adverse side-effect.

The side-effect is believed to be memory and concentration impairment reported by 20 to 29 percent of the users who take PPIs. These drugs are sold under the brand names as Nexium, Prevacid and Prilosec.

"The fact that this study found similar effects across three different sets of patients who are at different stages of cancer survivorship gives some weight to what we're seeing," said Kiecolt-Glaser, senior author of the paper and an investigator in Ohio State's Comprehensive Cancer Center. "Had it been in only a single study, it could have been a chance effect."

PPIs were approved by the U.S. Food and Drug Administration for short-term use in frequent gastric acid conditions and longer-term use for gastric ulcers and associated disorders involving excessive acid secretion. However, the research carried by investigators from Ohio State University concluded a relationship between breast cancer survivors' use of proton pump inhibitors (PPIs) and reports of problems with concentration and memory.

"The severity of the cognitive problems reported by PPI users in this study was comparable to what patients undergoing chemotherapy had reported in a large observational study," said Annelise Madison, lead author of the study and a graduate student in clinical psychology at Ohio State. "PPI non-users also reported problems, but were definitely getting better. Based on what we're seeing, we don't know if PPI users might not be able to fully recover cognitively after chemotherapy. It's an area for further investigation."

Learn more about the risks and benefits of proton pump inhibitors (PPIs):

Results of the findings were published in the Journal of Cancer Survivorship and was based on evaluations of mood responses and cognitive treatments. The study was supported by grants from the National Institutes of Health and was the first to examine PPI in breast cancer survivors.

"I thought there could be a cognitive effect from taking PPIs, particularly in this population, because breast cancer survivors are already at risk for cognitive decline," says gradute student Madison, who works in the lab of Janice Kiecolt-Glaser, professor of psychiatry and psychology. "PPIs are over the counter and generally considered safe so there haven't been many long-term trials, especially looking at cognitive outcomes, because nobody was really thinking that would be a downstream effect."

Source: Ohio State University

About the Author
  • Nouran earned her BS and MS in Biology at IUPUI and currently shares her love of science by teaching. She enjoys writing on various topics as well including science & medicine, global health, and conservation biology. She hopes through her writing she can make science more engaging and communicable to the general public.
You May Also Like
DEC 27, 2019
Drug Discovery & Development
DEC 27, 2019
Acne Drug Linked to 10 Suicides
UK regulators claim to have found a link between at least ten suicides and a powerful acne drug, manufactured under the names Roaccutane and Accutane. Alth...
JAN 16, 2020
Drug Discovery & Development
JAN 16, 2020
Fatty Acid Supplement Repairs Brain After Stroke in Mice
Researchers have found that supplements containing short chain fatty acids (SCFAs) may be able to help the brain recover from having a stroke. This comes a...
JAN 25, 2020
Drug Discovery & Development
JAN 25, 2020
Taking Psychedelics Improves Mood, says Yale Researchers
Psychedelics have long been known for their potential to enable deep reflection and modulate people’s moods. But evidence for this mostly came from a...
FEB 10, 2020
Drug Discovery & Development
FEB 10, 2020
Drug Prevents Coronavirus in Monkeys
An antiviral drug successfully prevented Middle East respiratory syndrome coronavirus (MERS-CoV) in infected rhesus macaques. The drug, Remdesivir, was adm...
FEB 24, 2020
Drug Discovery & Development
FEB 24, 2020
Leukemic Drugs May Target Lung Cancer
Two approved therapeutics for treating leukemia are currently being investigated for treatment-resistant lung cancer.  The findings were based on a li...
FEB 27, 2020
Drug Discovery & Development
FEB 27, 2020
New Drug Shows Promise in Treating Chronic Cough
Between 4% and 10% of adults around the world have an unexplainable chronic cough that has lasted for over 8 weeks. Although no treatments are currently av...
Loading Comments...